[The clofibrate-dipyridamole combination in the treatment of athero-arteriosclerotic vasculopathy].
A group of patients with athero-arteriosclerotic vascular disease (coronary heart disease and atherosclerosis of the extremities) have been subjected to platelet antiaggregating-antidyslipidaemic treatment with a chlofibrate-dipyridamol association; a control series was treated with chlofibrate alone. Frequency of angina pectoris, pain intensity and trinitrine consumption ware evaluated in patients with coronary heart disease, claudicometry, oscillometry and thermometry in patients with atherosclerosis of the extremities. The following laboratory parameters were also analysed: cholesterolaemia, triglyceridaemia, prothrombin activity, fibrinogenaemia, uricaemia and tolerance of oral glucose loading. Analysis of the results has shown that the association improved the parameters considered in statistically significant fashion; chlofibrate alone led to significant modifications of coronaropathic group parameters (with the exception of pain intensity) whereas it did not lead to significant changes in parameters evaluated for atherosclerosis of the extremities. All laboratory parameters were modified favourably by the association to a statistically greater extent than by chlofibrate alone. Both the association and chlofibrate were well tolerated.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy*; D002994:Clofibrate / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004176:Dipyridamole / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005951:Glucose Tolerance Test; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011516:Prothrombin / Q000032:analysis
D004338:Drug Combinations; D008055:Lipids; D004176:Dipyridamole; D011516:Prothrombin; D005340:Fibrinogen; D002994:Clofibrate
L'associazione clofibrato-dipiridamolo nel trattamento delle vasculopatie atero-arteriosclerotiche.